GALECTO, INC. (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 22nd, 2020 Company Industry Jurisdiction
GALECTO, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●] Subordinated Debt SecuritiesGalecto, Inc. • November 4th, 2021 • Pharmaceutical preparations • New York
Company FiledNovember 4th, 2021 Industry JurisdictionINDENTURE, dated as of [●], among GALECTO, INC., a corporation existing under the laws of the State of Delaware (the “Company”), and [TRUSTEE], as trustee (the “Trustee”):
OPEN MARKET SALE AGREEMENTSMGalecto, Inc. • November 4th, 2021 • Pharmaceutical preparations • New York
Company FiledNovember 4th, 2021 Industry JurisdictionGalecto, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.00001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
GALECTO, INC. [FORM OF] OFFICER INDEMNIFICATION AGREEMENTOfficer Indemnification Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 22nd, 2020 Company Industry JurisdictionThis Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc., a Delaware corporation (the “Company”), and [Officer Name] (“Indemnitee”). 1
GALECTO, INC. [FORM OF] DIRECTOR INDEMNIFICATION AGREEMENTDirector Indemnification Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 22nd, 2020 Company Industry JurisdictionThis Indemnification Agreement (“Agreement”) is made as of [Date] by and between Galecto, Inc, a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • October 22nd, 2020 • Galecto Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledOctober 22nd, 2020 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 25th day of September, 2020, by and among Galecto, Inc., a Delaware corporation (the “Company”), and each of the stockholders listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
Employment Contract Galecto Biotech ApS and Bertil E. LindmarkGalecto Inc. • October 7th, 2020 • Pharmaceutical preparations
Company FiledOctober 7th, 2020 Industry
SERVICE AGREEMENT March 2013Service Agreement • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
Contract Type FiledOctober 7th, 2020 Company Industry
Addendum to the Employment Contract Galecto Biotech ApS CVR no. 34 87 83 66 Ole Maal0es Vej 3 DK-2200 Copenhagen (the “Company’’) and Anders H. Pedersen (the “Employee’’) (each a “Party” and jointly the “Parties”) have today entered into this addendum...Galecto Inc. • October 7th, 2020 • Pharmaceutical preparations
Company FiledOctober 7th, 2020 Industry
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • October 7th, 2020 • Galecto Inc. • Pharmaceutical preparations
Contract Type FiledOctober 7th, 2020 Company IndustryThis amendment to the Employment Agreement of Jonathan Freve is made and entered into between Galecto, Inc. (the “Company”), and Jonathan Freve, (the “Employee” or “You”), (together, the “Parties”).
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMITTED INFORMATION HAS BEEN REPLACED BY ASTERISKSGalecto, Inc. • November 6th, 2023 • Pharmaceutical preparations
Company FiledNovember 6th, 2023 Industryhave today entered into this retention bonus agreement (the "Bonus Agreement") relating to the service agreement between the Parties, dated 23 April 2013 (the “Service Agreement”).
English Summary of a lease agreement dated May 4, 2020 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and COBIS A/S (the “Landlord”)Galecto Inc. • October 22nd, 2020 • Pharmaceutical preparations
Company FiledOctober 22nd, 2020 Industry• Modifications to leased Premises: Galecto is permitted to effect modifications to the leased premises only with the prior written approval of the Landlord. Galecto and the Landlord will agree on the costs, reimbursement and potential obligations to build-back modifications.
September 26, 2023 Jonathan Freve [Address Omitted] Re: Retention Compensation Dear Jon:Galecto, Inc. • November 6th, 2023 • Pharmaceutical preparations • Massachusetts
Company FiledNovember 6th, 2023 Industry JurisdictionAs you know, Galecto, Inc. (or its affiliate as applicable, the “Company”) greatly appreciates your efforts and hopes to continue working with you in the future. In order to encourage your continued efforts for the Company, the Company is offering you the opportunity to receive retention compensation as specified below, subject to this “Agreement”:
EMPLOYMENT CONTRACT December 2012Galecto Inc. • October 7th, 2020 • Pharmaceutical preparations
Company FiledOctober 7th, 2020 Industry
ContractGalecto, Inc. • August 5th, 2021 • Pharmaceutical preparations
Company FiledAugust 5th, 2021 IndustryEnglish Summary of a lease agreement dated April 15, 2021 (the “Lease”) by and between Galecto Biotech ApS (“Galecto”) and Symbion A/S (the “Landlord”)